Detalhe da pesquisa
1.
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Invest New Drugs
; 32(6): 1181-7, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24879333
2.
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Gynecol Oncol
; 127(1): 63-9, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22772063
3.
Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
Am Heart J
; 157(5): 827-36, 836.e1, 2009 May.
Artigo
Inglês
| MEDLINE | ID: mdl-19376308
4.
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.
Eur J Cancer
; 44(4): 494-500, 2008 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-18024014
5.
Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development.
Clin Pharmacol Ther
; 103(1): 47-49, 2018 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29134636
6.
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Clin Cancer Res
; 10(15): 5048-57, 2004 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15297406
7.
Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
J Clin Pharmacol
; 55(3): 336-47, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25302940
8.
Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Anticancer Res
; 24(2C): 1121-5, 2004.
Artigo
Inglês
| MEDLINE | ID: mdl-15154634
9.
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.
Leuk Res Rep
; 3(2): 58-61, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25068104
10.
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
J Clin Oncol
; 32(1): 44-50, 2014 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24043741
11.
Cardiac safety, risk management, and oncology drug development.
Clin Cancer Res
; 12(12): 3646-7, 2006 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16778090
12.
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Clin Cancer Res
; 18(17): 4775-84, 2012 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22767670
13.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
J Clin Oncol
; 30(13): 1527-33, 2012 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22454420
14.
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 18(17): 4764-74, 2012 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22753585
15.
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 67(4): 945-54, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20607239
16.
Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.
J Clin Oncol
; 21(17): 3378-9, 2003 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12947082
17.
Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer.
Clin Cancer Res
; 10(17): 5967-8; author reply 5968-9, 2004 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15355930
18.
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
Mol Cancer Ther
; 9(10): 2844-52, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20724522
19.
Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.
AAPS J
; 8(1): E89-94, 2006 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-16584137
20.
Brain natriuretic peptide: potential adjunct for cardiac risk assessment and management during treatment with experimental anticancer agents.
AAPS J
; 9(2): E115-6, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-18989790